118
Participants
Start Date
December 12, 2023
Primary Completion Date
May 29, 2025
Study Completion Date
July 10, 2025
GNR-086
GNR-086 is administered as a subcutaneous injection at a dose of 4 mg/kg once every 4 weeks for 24 weeks.
Ilaris®
Ilaris® is administered as a subcutaneous injection at a dose of 4 mg/kg once every 4 weeks for 24 weeks.
Limited Liability Company "OLLA-MED", Moscow
Federal State Budgetary Institution "Research Institute of Rheumatology named after V.A. Nasonova", Moscow
State budgetary healthcare institution of the city of Moscow "City Clinical Hospital No. 52 of the Moscow Health Department" (GBUZ "City Clinical Hospital No. 52 DZM"), Moscow
Federal State Autonomous Educational Institution of Russian National Research Medical University named after. N. I. Pirogova, Moscow
"Federal State Autonomous Educational Institution of Russian National Research Medical University named after. N.I. Pirogov Ministry of Health of Russia Separate structural unit Russian Gerontological Scientific and Clinical Center", Moscow
"State Budgetary Healthcare Institution Clinical Hospital No. 2", Yaroslavl
Limited Liability Company "Medical Technologies" LLC "Medical Technologies", Saint Petersburg
Limited Liability Company "Ex Seven Clinical Research", Saint Petersburg
Limited Liability Company "Interleukin", Saint Petersburg
State Budgetary Healthcare Institution Leningrad area Clinical Hospital, Saint Petersburg
Private foundation "RZD-Medicine" Smolensk", Smolensk
State health care institution city clinical hospital №25, Volgograd
State budgetary healthcare institution "Chelyabinsk Regional Clinical Hospital", Chelyabinsk
Federal State Budgetary Educational Institution of Higher Education Orenburg State Medical University of the Ministry of Health of Russia, Orenburg
Limited Liability Company "BioMed", Vladimir
Limited Liability Company "Medical Center "Healthy Family", Novosibirsk
Limited Liability Company "Medical Center "Revma-Med", Kemerovo
AO GENERIUM
INDUSTRY